Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Are These Moves Higher Well-Deserved? Zynga Inc (ZNGA), Oncolytics Biotech, Inc. (ONCY) and More

Page 1 of 2

On Friday, we saw an unusual amount of volatility in many stocks during a day of slight gains for the broader market. Typically, it doesn’t take a lot for a stock to trade with gains between 5% and 20% in a session; it can be caused by an analyst’s remarks or sometimes it’s caused by earnings. Sometimes the moves are warranted and other times they are not. Therefore, I am looking at several moves higher to determine if the stocks are presenting value or a value trap.

Zynga Inc (NASDAQ:ZNGA)Gaming Stock Rallies Due to Several Speculative Catalysts

On Friday, online social game company Zynga Inc (NASDAQ:ZNGA) rallied 11%, making its five day return almost 30%. The stock traded higher for a number of reasons: 1) new in New Jersey about Governor Christie being onboard with online poker, 2) better than expected earnings, and 3) LinkedIn posted a blowout quarter than pushed several social media stocks higher. However, only one of these “catalysts” was connected to Zynga, its earnings.

LinkedIn has a completely different business model and Zynga is still several years from being able to profit from online gambling. Might I add, Zynga’s earnings were not good, yet cost cutting made them appear decent. This is a tricky call; the stock is lower by 75% over the last year and Zynga trades with the most attractive price/sales ratio in the social media space. With that being said, much of its upside is connected to the prospects of online gambling, as problems with sustainability still exist. Therefore, I say the news was not worth the move and that it’s a value trap until fundamental improvements occur as a result of these three “catalysts.”

Biotech Stocks Rises After Data

When a biotechnology stock moves higher after good data I always ask myself one fundamental question, “what else is needed for an FDA approval?” I almost treat a Phase study like a checklist, and everytime one barrier is crossed I look to the next measure of efficiency. However, Oncolytics Biotech, Inc. (NASDAQ:ONCY) allowed me to add a big mark on my checklist when they announced positive results from a mid-stage study examining the use of Reolysin in helping to shrink tumors.

The company said that 95% of patients with squamous cell carcinoma of the lung who used the product exhibited overall tumor shrinkage. Now, we turn out attention to larger studies and survival, if the drug maintains these results then we have an FDA approved product on our hands. So far, all looks good, but I will caution that with a $330 million market cap it’s expensive for a company with a lead product being a mid-stage product. Therefore, I might wait for a slight pullback.

A Fundamental Beat that Leads to Gains

Synchronoss Technologies, Inc. (NASDAQ:SNCR) posted Q4 earnings that beat on both the top and bottom line with growth of 19% year-over-year and the stock rallied almost 20%! This is a small cap company that saw a strong beat in all measures including operating margins of 25%, in the software and programming industry.  The company continues to grow with a strong balance sheet and solid cash flow. Furthermore, the stock is not overvalued, rather fairly valued compared to growth, meaning it could make a good longer term investment for those of you who believe in its long-term future.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!